Since RIP1-mediated NF-κB activation is mediated by its intermediate domain independently its kinase activity32–34, inhibitors that specifically target the intermediate domain of RIP1 may be useful in improving the therapeutic efficacy of BRAF/MEK inhibitors in the treatment of melanoma. This evidence concerns the gene BRAF and melanoma.